{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:35:38Z","timestamp":1777419338100,"version":"3.51.4"},"reference-count":10,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,24]],"date-time":"2021-04-24T00:00:00Z","timestamp":1619222400000},"content-version":"am","delay-in-days":388,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.clbc.2020.01.009","type":"journal-article","created":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T00:47:09Z","timestamp":1582159629000},"page":"e192-e195","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Severe Cellular Immunodeficiency Triggered by the CDK4\/6 Inhibitor Palbociclib"],"prefix":"10.1016","volume":"20","author":[{"given":"Zo\u00e9","family":"Guillaume","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques","family":"Medioni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnes","family":"Lillo-Lelouet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gr\u00e9goire","family":"Marret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phane","family":"Oudard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audrey","family":"Simonaggio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2020.01.009_bib1","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clbc.2020.01.009_bib2","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","volume":"17","author":"Cristofanilli","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2020.01.009_bib3","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1634\/theoncologist.2019-0019","article-title":"Palbociclib with letrozole in postmenopausal women with ER+\/HER2- advanced breast cancer: hematologic safety analysis of the randomized PALOMA-2 trial","volume":"24","author":"Di\u00e9ras","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.clbc.2020.01.009_bib4","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S1535-6108(03)00301-5","article-title":"Requirement for cyclin D3 in lymphocyte development and T cell leukemias","volume":"4","author":"Sicinska","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clbc.2020.01.009_bib5","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S1535-6108(03)00305-2","article-title":"No T without D3: a critical role for cyclin D3 in normal and malignant precursor T cells","volume":"4","author":"Weng","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clbc.2020.01.009_bib6","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1158\/1078-0432.CCR-11-0509","article-title":"Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4\/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer","volume":"18","author":"Flaherty","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clbc.2020.01.009_bib7","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1093\/annonc\/mdz198","article-title":"A\u00a0phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor positive invasive breast carcinoma","volume":"30","author":"Mayer","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2020.01.009_bib8","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1080\/03007995.2017.1325730","article-title":"Comparison of palbociclib in combination with letrozole or fulvestrant with endocrine therapies for advanced\/metastatic breast cancer: network meta-analysis","volume":"33","author":"Chirila","year":"2017","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clbc.2020.01.009_bib9","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1056\/NEJMoa1810527","article-title":"Overall survival with palbociclib and fulvestrant in advanced breast cancer","volume":"379","author":"Turner","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clbc.2020.01.009_bib10","doi-asserted-by":"crossref","first-page":"212550","DOI":"10.7573\/dic.212550","article-title":"Oral oncolytic and antiretroviral therapy administration: dose adjustments, drug interactions, and other considerations for clinical use","volume":"8","author":"Badowski","year":"2019","journal-title":"Drugs Context"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820920300252?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820920300252?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:19:44Z","timestamp":1761513584000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820920300252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S1526820920300252"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2020.01.009","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Severe Cellular Immunodeficiency Triggered by the CDK4\/6 Inhibitor Palbociclib","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2020.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}